p.87 抽出テキスト
CLINICAL STATEMENTS AND GUIDELINES September 16, 2025 Circulation. 2025;152:e114–e218. DOI: 10.1161/CIR.0000000000001356 e200 6 Persu A, De Plaen JF. Recent insights in the development of organ damage caused by hypertension. Acta Cardiol. 2004;59:369–381. 7. Allen NB, Siddique J, Wilkins JT, et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA. 2014;311:490–497. 8. Pletcher MJ, Bibbins-Domingo K, Lewis CE, et al. Prehypertension dur ing young adulthood and coronary calcium later in life. Ann Intern Med. 2008;149:91–99. 9. Juhola J, Magnussen CG, Berenson GS, et al. Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis: the In ternational Childhood Cardiovascular Cohort Consortium. Circulation. 2013;128:217–224. 10. Cuspidi C, Sala C, Tadic M, et al. Pre-hypertension and subclinical carotid damage: a meta-analysis. J Hum Hypertens. 2019;33:34–40. 11. Lembo M, Pacella D, Manzi MV, et al. Hypertension-mediated organ dam age involving multiple sites is an independent risk factor for cardiovascular events. Eur Heart J Open. 2023;3:oead102. 12. Suvila K, Niiranen TJ. Interrelations between high blood pressure, organ damage, and cardiovascular disease: no more room for doubt. Hypertension. 2022;79:516–517. 13. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116. 5.3.1 Diabetes 1 Rahman F, McEvoy JW, Ohkuma T, et al. Effects of blood pressure low ering on clinical outcomes according to baseline blood pressure and car diovascular risk in patients with type 2 diabetes mellitus. Hypertension. 2019;73:1291–1299. 2. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabe tes: a systematic review and meta-analysis. JAMA. 2015;313:603–615. 3. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hyper tension in people with diabetes mellitus. Cochrane Database Syst Rev 2013;CD008277. 4. Yang Q, Zheng R, Wang S, et al. Systolic blood pressure control targets to prevent major cardiovascular events and death in patients with type 2 diabetes: a systematic review and network meta-analysis. Hypertension. 2023;80:1640–1653. 5. Bi Y, Li M, Liu Y, et al. Intensive blood-pressure control in patients with type 2 diabetes (BPROAD). N Engl J Med. 2025;392:1155–1167. 6. Hansson L, Zanchetti A, Carruthers SG, et al, HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hy pertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762. 7. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihyperten sive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:1401–1409. 8. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing endstage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:1499–1507. 9. Strippoli GF, Bonifati C, Craig M, et al. Angiotensin converting enzyme inhibi tors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006;2006:CD006257. 10. Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–2056. 11. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208–1219. 12. Mann JF, Gerstein HC, Yi QL, et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Out comes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis. 2003;42:936–942. 13. Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J. 1991;121:1268–1273. 14. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444. 15. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116. 16. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–1585. 17. Wu W, Tong HM, Li YS, et al. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis. Endo crine. 2024;83:571–584. 18 Solomon SD, Rice MM, K AJ, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006;114:26–31. 5.3.2 Obesity and Metabolic Syndrome 1 Wilding JP, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989– 1002. 2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–2232. 3. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327:138–150. 4. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglu tide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403–1413. 5. de Lemos JA, Linetzky B, le Roux CW, et al. Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index ≥27 kg/m2: SURMOUNT-1 ambulatory blood pressure monitoring substudy. Hyperten sion. 2024;81:e41-e43. 6. Schiavon CA, Cavalcanti AB, Oliveira JD, et al. Randomized trial of effect of bariatric surgery on blood pressure after 5 years. J Am Coll Cardiol. 2024;83:637–648. 7. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardio vascular risk: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–1132. 8. Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Associa tion. Circulation. 2023;148:1636–1664. 9. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidneymetabolic health: a presidential advisory from the American Heart Associa tion. Circulation. 2023;148:1606–1635. 10. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart disease and stroke statistics: a report of US and global data from the American Heart Associa tion. Circulation. 2024;149:e347-e913. 11. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly sub cutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414–1425. 12. King WC, Hinerman AS, Belle SH, et al. Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes. JAMA. 2018;320:1560–1569. 13. Kennedy C, Hayes P, Salama S, et al. The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and metaanalysis. J Hypertens. 2023;41:e11. 14. Liu D, Huang Y, Huang C, et al. Calorie restriction with or without time-restricted eating in weight loss. N Engl J Med. 2022;386:1495– 1504. 15. Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377:1143–1155. 5.3.3 Chronic Coronary Disease 1 Carrick D, Haig C, Maznyczka AM, et al. Hypertension, microvascular pa thology, and prognosis after an acute myocardial infarction. Hypertension. 2018;72:720–730. 2. Wright JT Jr, Williamson JD, Whelton PK, et al. Sprint Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116. 3. Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775–781. 4. Lewis CE, Fine LJ, Beddhu S, et al. Sprint Research Group. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021;384:1921–1930. 5. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/ NLA/PCNA guideline for the management of patients with chronic coro nary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9–e119. Downloaded from http://ahajournals.org by on October 7, 2026